AbbVie announces CHMP recommendation for Tepkinly in follicular lymphoma
Drug ApprovalAccelerated ApprovalClinical Result
Preview
Source: PMLiVE
AbbVie has announced that its IgG1-bispecific antibody Tepkinly (epcoritamab) has been recommended by the European Medicines Agency’s human medicines committee to treat specific cases of follicular lymphoma (FL).
The Committee for Medicinal Products for Human Use (CHMP) has recommended that the drug, which is being co-developed by AbbVie and Genmab as part of the companies’ oncology collaboration, be granted conditional marketing authorisation as a monotherapy for adults with relapsed or refractory (R/R) FL who have received at least two prior therapies.
The CHMP’s recommendation of the therapy was supported by positive results from the phase 1/2 EPCORE NHL-1 clinical trial, which evaluated the safety and efficacy of Tepkinly in more than 120 adults with R/R FL.
FL is the second-most common form of non-Hodgkin lymphoma, accounting for up to 30% of all cases. The disease is considered incurable, with patients frequently relapsing and the prognosis worsening after each subsequent relapse.
Mariana Cota Stirner, vice president, therapeutic area head for haematology at AbbVie, said: “Patients with FL are likely to face disease recurrence and shorter durability of response with each subsequent line of treatment.
“This positive opinion recognises the unmet need in the EU for individuals with R/R FL, following failure of other therapies.”
AbbVie announced earlier this year that Tepkinly had been recommended by the National Institute for Health and Care Excellence to treat certain adults with diffuse large B-cell lymphoma (DLBCL).
The agency’s decision specifically applies to patients who have DLBCL that has returned or not responded to at least two previous treatments, including Roche’s CD79b-directed antibody-drug conjugate Polivy (polatuzumab vedotin), unless this is contraindicated or not tolerated.
AbbVie and Genmab also received accelerated approval by the US Food and Drug Administration (FDA) last month for epcoritamab, under the brand name Epkinly, to treat adults with R/R FL.
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Chat with Hiro
Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.